United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2024. Projections are model estimates, not investment advice.
Want the full financial forecast report for Can-Fite BioPharma Ltd.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -134.94% | 0.94% | 1.84% | 1.29% | 1.27% | 1.42% |
| ROA | -82.47% | 0.55% | 1.05% | 0.72% | 0.69% | 0.75% |
| Gross Margin | 100% | 88.5% | 88.25% | 88.11% | 87.81% | 87.84% |
| Total Assets | $9,120.00K | $9,463.60K | $9,834.69K | $10,235.46K | $10,668.30K | $11,135.76K |
| Net Income | -$7,880.00K | $51.38K | $101.70K | $72.72K | $72.53K | $81.78K |
| Valuation | $10,669.28K | $10,961.00K | $11,196.57K | $11,486.85K | $11,793.53K | $12,103.78K |
| Stock Price | $3.29 | $3.38 | $3.45 | $3.54 | $3.64 | $3.73 |